Randomized phase III trial results of Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

Tara Beers Gibson, Aarati Ranganathan, Axel F Grothey

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC; mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epidermal growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial, which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC, have recently been reported. Panitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%. Rash was reported in 90% of patients, with increased severity significantly correlated with improved median overall survival (OS). Further clinical studies are ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.

Original languageEnglish (US)
Pages (from-to)29-31
Number of pages3
JournalClinical Colorectal Cancer
Volume6
Issue number1
DOIs
StatePublished - 2006

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Monoclonal Antibodies
Combination Drug Therapy
Risk Reduction Behavior
Exanthema
Colonic Neoplasms
Patient Care
Therapeutics
Clinical Trials
Safety
Survival
panitumumab
Neoplasms

Keywords

  • Best supportive care
  • Skin-related toxicities
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Randomized phase III trial results of Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. / Gibson, Tara Beers; Ranganathan, Aarati; Grothey, Axel F.

In: Clinical Colorectal Cancer, Vol. 6, No. 1, 2006, p. 29-31.

Research output: Contribution to journalArticle

@article{25253e2aeeed4d06aa47bb8528c76750,
title = "Randomized phase III trial results of Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer",
abstract = "Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC; mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epidermal growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial, which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC, have recently been reported. Panitumumab therapy resulted in a 46{\%} reduction in the risk of tumor progression and a partial response rate of 8{\%}. Rash was reported in 90{\%} of patients, with increased severity significantly correlated with improved median overall survival (OS). Further clinical studies are ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.",
keywords = "Best supportive care, Skin-related toxicities, Survival",
author = "Gibson, {Tara Beers} and Aarati Ranganathan and Grothey, {Axel F}",
year = "2006",
doi = "10.3816/CCC.2006.n.01",
language = "English (US)",
volume = "6",
pages = "29--31",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Randomized phase III trial results of Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

AU - Gibson, Tara Beers

AU - Ranganathan, Aarati

AU - Grothey, Axel F

PY - 2006

Y1 - 2006

N2 - Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC; mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epidermal growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial, which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC, have recently been reported. Panitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%. Rash was reported in 90% of patients, with increased severity significantly correlated with improved median overall survival (OS). Further clinical studies are ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.

AB - Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC; mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epidermal growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial, which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC, have recently been reported. Panitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%. Rash was reported in 90% of patients, with increased severity significantly correlated with improved median overall survival (OS). Further clinical studies are ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.

KW - Best supportive care

KW - Skin-related toxicities

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33745909120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745909120&partnerID=8YFLogxK

U2 - 10.3816/CCC.2006.n.01

DO - 10.3816/CCC.2006.n.01

M3 - Article

C2 - 16796788

AN - SCOPUS:33745909120

VL - 6

SP - 29

EP - 31

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 1

ER -